TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Study acronym: TAPUR
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 111 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Interventions modified
    • Trial arms changed: 13 → 12
    • Eligibility criteria expanded, about 20 words
    • Site details revised at 58 of 181 sites
  2. Interventions modified
    • Trial arms changed: 15 → 13
    • Eligibility criteria shortened, about 80 words
    • Site details revised at 66 of 181 sites
    v110
  3. Trial sites expanded: 174 → 181 locationsv109
  4. Site contacts updated at 2 of 174 sitesv108
  5. Study sites: 175 to 174v107
  6. Trial sites expanded: 166 → 174 locationsv106
  7. Study sites: 166 to 174v105
  8. Study sites: 160 to 166v104
  9. Interventions: Abemaciclib (Drug), Atezolizumab and PHESGO (Drug), Atezolizumab and Talazoparib (Drug), Entrectinib (Drug), Futibatinib (Drug)… to Abemaciclib (Drug), Atezolizumab and Talazoparib (Drug), Dabrafenib plus Trametinib (Drug), Fam-Trastuzumab Deruxtecan-Nxki (TDxD) (Drug)…
    • Collaborators: 10 to 11
    • Study arms: 17 to 15
    • Eligibility criteria expanded, about 4 words
    v103
  10. Site contacts updated at 61 of 160 sitesv102
  11. Study sites revised (160)v101
  12. Site contacts updated at 1 of 160 sitesv100
  13. Site details revised at 1 of 160 sitesv99
  14. Site contacts updated at 5 of 160 sitesv98
  15. Site contacts updated at 1 of 160 sitesv97
  16. Site contacts updated at 1 of 160 sitesv96
  17. Site contacts updated at 2 of 160 sitesv95
  18. Site contacts updated at 129 of 160 sitesv94
  19. Primary completion date: Jun 30, 2026 to Dec 31, 2027
    • Enrollment target: 3791 to 4200
    • Study completion date: Jun 30, 2027 to Dec 31, 2028
    • Site contacts updated at 129 of 160 sites
    v93
  20. Site details revised at 1 of 160 sitesv92
  21. Study sites: 157 to 160v91
  22. Study sites: 156 to 157v90
  23. Site contacts updated at 3 of 156 sitesv89
  24. Study sites: 160 to 156v88
  25. Site contacts updated at 123 of 160 sitesv87
  26. Site contacts updated at 1 of 160 sitesv86
  27. Site contacts updated at 2 of 160 sitesv85
  28. Site contacts updated at 1 of 160 sitesv84
  29. Primary completion date: Dec 31, 2024 to Jun 30, 2026
    • Study completion date: Dec 31, 2025 to Jun 30, 2027
    v83
  30. Site contacts updated at 1 of 160 sitesv82
  31. Study sites: 162 to 160v81
  32. Study sites: 161 to 162v80
  33. Site contacts updated at 1 of 161 sitesv79
  34. Site details revised at 34 of 161 sitesv78
  35. Site contacts updated at 1 of 161 sitesv77
  36. Site contacts updated at 2 of 161 sitesv76
  37. Site contacts updated at 2 of 161 sitesv75
  38. 2 versions Re-verified since Oct 27, 2023, no change to tracked fieldsv73-v74
  39. Study sites: 173 to 161v72
  40. Site contacts updated at 18 of 173 sitesv71
  41. Study sites: 144 to 173v70
  42. Study sites revised (144)v69
  43. Site contacts updated at 5 of 144 sitesv68
  44. Study sites: 128 to 144v67
  45. Site contacts updated at 1 of 128 sitesv66
  46. Site contacts updated at 1 of 128 sitesv65
  47. Enrollment target: 3641 to 3791
    • Site contacts updated at 1 of 128 sites
    v64
  48. Study sites: 126 to 128
    • Interventions: Abemaciclib (Drug), Afatinib (Drug), Atezolizumab and PHESGO (Drug), Atezolizumab and Talazoparib (Drug), Crizotinib (Drug), Entrectinib… to Abemaciclib (Drug), Atezolizumab and PHESGO (Drug), Atezolizumab and Talazoparib (Drug), Entrectinib (Drug), Futibatinib (Drug)…
    • Study arms: 18 to 17
    v63
  49. Re-verified, no change to tracked fieldsv62
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Trial Details
NCT Number NCT02693535
Lead Sponsor American Society of Clinical Oncology
Collaborators: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Pfizer, Taiho Oncology, Inc., Novartis, Merck Institute for Therapeutic Research, Boehringer Ingelheim, Seattle Genetics (now a wholly owned subsidiary of Pfizer)
Conditions
(from sponsor)		 Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Related terms Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms
Enrollment 4,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov